Orum Therapeutics closed about $100 million (146 billion won) to advance its degrader‑antibody conjugate (DAC) platform and lead oncology candidates, shifting focus after safety issues halted a HER2 program. The Cambridge‑and‑Daejeon company is prioritizing ORM‑1153 targeting CD123 in acute myeloid leukemia and plans clinical entry by late 2026. Orum’s DAC approach replaces cytotoxic payloads with protein‑degrading chemistry, aiming to overcome resistance to conventional ADCs. The financing supports continued IND enabling work and highlights investor interest in next‑generation targeted payloads that expand ADC utility in hematologic malignancies.